Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.31 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.31 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.30 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25827054 | 0.91 | POLRMT (0.36) | POLRMTRNASELP2RX1P2RX3P2RX2 | |
| SCHEMBL25826065 | 0.87 | POLRMT (0.44) | POLRMTP2RY2P2RX1P2RX3P2RX2 | |
| SCHEMBL25826041 | 0.83 | RNASEL (0.42) | POLRMTP2RY2RNASELP2RX1P2RX3 | |
| SCHEMBL25826846 | 0.81 | TMPRSS2 (0.32) | TMPRSS2 | |
| SCHEMBL25826990 | 0.79 | PIK3CD (0.32) | TMPRSS2 | |
| SCHEMBL25827006 | 0.77 | PIK3CD (0.31) | TMPRSS2 | |
| SCHEMBL25821565 | 0.73 | RNASEL (0.42) | POLRMTP2RY2RNASELP2RX1P2RX3 | |
| SCHEMBL25821559 | 0.73 | RNASEL (0.42) | POLRMTP2RY2RNASELP2RX1P2RX3 | |
| SCHEMBL25826835 | 0.72 | TMPRSS2 (0.47) | TMPRSS2 | |
| SCHEMBL25826852 | 0.71 | ACVRL1 (0.35) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | POLRMT 139/4885P2RY2 276/4885RNASEL 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.